2024

Rankin, S. et al. (2024) Arterial effects of anthracycline: structural & inflammatory assessments in non-human primates and lymphoma patients. Clinical Science, (doi: 10.1042/CS20241529) (Accepted for Publication)

Estcourt, L. J. et al. (2024) Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial. Lancet Haematology, (doi: 10.1016/S2352-3026(24)00317-X) (PMID:39642900) (Early Online Publication)

Rankin, S. et al. (2024) Arterial effects of anthracycline: structural and inflammatory assessments in non-human primates and lymphoma patients using 18F-FDG positron emission tomography. bioRxiv, (doi: 10.1101/2024.05.30.596741)

Bouttell, J. , Fraser, H. , Goodlad, J. R., Hopkins, D. , McKay, P., Oien, K. A. , Seligmann, B., Von Delft, S. and Hawkins, N. (2024) Adding a gene expression profile test to aid differential diagnosis and treatment in aggressive large B-cell lymphoma: an early exploratory economic evaluation. Applied Health Economics and Health Policy, 22(2), pp. 243-254. (doi: 10.1007/s40258-023-00845-1) (PMID:38017318)

Wilson, M. R. et al. (2024) Dosage of high‐dose methotrexate as CNS prophylaxis in DLBCL: A detailed analysis of toxicity and impact on CNS relapse. American Journal of Hematology, 99(2), E46-E50. (doi: 10.1002/ajh.27167) (PMID:38037530)

2023

Henriksen, P. A. et al. (2023) Multicenter, prospective, randomized controlled trial of high-sensitivity cardiac troponin I–guided combination angiotensin receptor blockade and beta-blocker therapy to prevent anthracycline cardiotoxicity: The Cardiac CARE trial. Circulation, 148(21), pp. 1680-1690. (doi: 10.1161/CIRCULATIONAHA.123.064274) (PMID:37746692) (PMCID:PMC10655910)

Wilson, M. R. et al. (2023) ‘ACOPP’ chemotherapy for older and less fit patients with Hodgkin lymphoma—a multicentre, retrospective study. British Journal of Haematology, 202(4), pp. 796-800. (doi: 10.1111/bjh.18947) (PMID:37357380)

2022

Henriksen, P. A. et al. (2022) Rationale and design of the Cardiac CARE trial: A randomized trial of troponin-guided neurohormonal blockade for the prevention of anthracycline cardiotoxicity. Circulation: Heart Failure, 15(7), e009445. (doi: 10.1161/CIRCHEARTFAILURE.121.009445) (PMID:35766037)

Wilson, M. R. et al. (2022) Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients. Blood, 139(16), pp. 2499-2511. (doi: 10.1182/blood.2021014506) (PMID:34995350)

2021

Martinez-Calle, N., Wilson, M. R. , Eyre, T. A., Cwynarski, K., McKay, P. and Fox, C. P. (2021) Interpretation of retrospective data evaluating high-dose methotrexate as central nervous system prophylaxis in diffuse large B-cell lymphoma; caution required. American Journal of Hematology, 96(9), E338-E339. (doi: 10.1002/ajh.26257) (PMID:34050962)

Rampotas, A. et al. (2021) Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: a UK and Ireland analysis. British Journal of Haematology, 194(2), pp. 365-377. (doi: 10.1111/bjh.17513) (PMID:33959947)

McCulloch, R. et al. (2021) Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real‐world analysis of outcomes in 211 patients. British Journal of Haematology, 193(2), pp. 290-298. (doi: 10.1111/bjh.17363) (PMID:33620106)

Oun, H., Wilson, M. , Leach, M. and McKay, P. (2021) Central nervous system relapse of primary cutaneous CD8+ aggressive epidermotropic cytotoxic T‐cell lymphoma. British Journal of Haematology, 193(1), p. 9. (doi: 10.1111/bjh.17267) (PMID:33336793)

2020

McKay, P., Wilson, M. R. , Chaganti, S., Smith, J., Fox, C. P. and Cwynarski, K. (2020) The prevention of central nervous system relapse in diffuse large B‐cell lymphoma: a British Society for Haematology good practice paper. British Journal of Haematology, 190(5), pp. 708-714. (doi: 10.1111/bjh.16866) (PMID:32433789)

Wilson, M. R. et al. (2020) Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery. Blood Advances, 4(15), pp. 3586-3593. (doi: 10.1182/bloodadvances.2020002421) (PMID:32761231) (PMCID:PMC7422120)

2019

Wilson, M. R. , McKay, P. and Leach, M. (2019) Primary leptomeningeal B‐cell lymphoma. British Journal of Haematology, 187(4), p. 412. (doi: 10.1111/bjh.16163) (PMID:31423572)

Wilson, M. R. , Bagguley, T., Smith, A., Roman, E., Patmore, R., Hanlon, K., Leach, M., Burton, C. and McKay, P. (2019) Frontline management of nodular lymphocyte predominant Hodgkin lymphoma – a retrospective UK multicentre study. British Journal of Haematology, 186(6), e214-e217. (doi: 10.1111/bjh.16109) (PMID:31344253)

2014

Hamilton, R., Andrews, I., McKay, P. and Leach, M. (2014) Loss of utility of bone marrow biopsy as a staging evaluation for Hodgkin lymphoma in the positron emission tomography–computed tomography era: a West of Scotland study. Leukemia and Lymphoma, 55(5), pp. 1049-1052. (doi: 10.3109/10428194.2013.821201)

2013

Forbes, A., Farrell, K., McKay, P., Bolam, S. and Rule, S. (2013) High dose cytarabine with rituximab is an effective first-line therapy for mantle cell lymphoma and produces ample stem cell harvest yields after multiple chemotherapy cycles. Leukemia and Lymphoma, 54(10), pp. 2303-2305. (doi: 10.3109/10428194.2013.769536)

2012

McKay, P., Leach, M., Jackson, R., Cook, G. and Rule, S. (2012) Guidelines for the investigation and management of mantle cell lymphoma. British Journal of Haematology, 159(4), pp. 405-426. (doi: 10.1111/bjh.12046)

2011

Farrell, K., McKay, P. and Leach, M. (2011) Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year followup in the West of Scotland Cancer Network. Leukemia and Lymphoma, 52(10), pp. 1920-1928. (doi: 10.3109/10428194.2011.584993)

2008

Bray, C.A., Morrison, D.S. and McKay, P. (2008) Socio-economic deprivation and survival of non-Hodgkin lymphoma in Scotland. Leukemia and Lymphoma, 49(5), pp. 917-923.

Articles

Rankin, S. et al. (2024) Arterial effects of anthracycline: structural & inflammatory assessments in non-human primates and lymphoma patients. Clinical Science, (doi: 10.1042/CS20241529) (Accepted for Publication)

Estcourt, L. J. et al. (2024) Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial. Lancet Haematology, (doi: 10.1016/S2352-3026(24)00317-X) (PMID:39642900) (Early Online Publication)

Rankin, S. et al. (2024) Arterial effects of anthracycline: structural and inflammatory assessments in non-human primates and lymphoma patients using 18F-FDG positron emission tomography. bioRxiv, (doi: 10.1101/2024.05.30.596741)

Bouttell, J. , Fraser, H. , Goodlad, J. R., Hopkins, D. , McKay, P., Oien, K. A. , Seligmann, B., Von Delft, S. and Hawkins, N. (2024) Adding a gene expression profile test to aid differential diagnosis and treatment in aggressive large B-cell lymphoma: an early exploratory economic evaluation. Applied Health Economics and Health Policy, 22(2), pp. 243-254. (doi: 10.1007/s40258-023-00845-1) (PMID:38017318)

Wilson, M. R. et al. (2024) Dosage of high‐dose methotrexate as CNS prophylaxis in DLBCL: A detailed analysis of toxicity and impact on CNS relapse. American Journal of Hematology, 99(2), E46-E50. (doi: 10.1002/ajh.27167) (PMID:38037530)

Henriksen, P. A. et al. (2023) Multicenter, prospective, randomized controlled trial of high-sensitivity cardiac troponin I–guided combination angiotensin receptor blockade and beta-blocker therapy to prevent anthracycline cardiotoxicity: The Cardiac CARE trial. Circulation, 148(21), pp. 1680-1690. (doi: 10.1161/CIRCULATIONAHA.123.064274) (PMID:37746692) (PMCID:PMC10655910)

Wilson, M. R. et al. (2023) ‘ACOPP’ chemotherapy for older and less fit patients with Hodgkin lymphoma—a multicentre, retrospective study. British Journal of Haematology, 202(4), pp. 796-800. (doi: 10.1111/bjh.18947) (PMID:37357380)

Henriksen, P. A. et al. (2022) Rationale and design of the Cardiac CARE trial: A randomized trial of troponin-guided neurohormonal blockade for the prevention of anthracycline cardiotoxicity. Circulation: Heart Failure, 15(7), e009445. (doi: 10.1161/CIRCHEARTFAILURE.121.009445) (PMID:35766037)

Wilson, M. R. et al. (2022) Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients. Blood, 139(16), pp. 2499-2511. (doi: 10.1182/blood.2021014506) (PMID:34995350)

Martinez-Calle, N., Wilson, M. R. , Eyre, T. A., Cwynarski, K., McKay, P. and Fox, C. P. (2021) Interpretation of retrospective data evaluating high-dose methotrexate as central nervous system prophylaxis in diffuse large B-cell lymphoma; caution required. American Journal of Hematology, 96(9), E338-E339. (doi: 10.1002/ajh.26257) (PMID:34050962)

Rampotas, A. et al. (2021) Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: a UK and Ireland analysis. British Journal of Haematology, 194(2), pp. 365-377. (doi: 10.1111/bjh.17513) (PMID:33959947)

McCulloch, R. et al. (2021) Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real‐world analysis of outcomes in 211 patients. British Journal of Haematology, 193(2), pp. 290-298. (doi: 10.1111/bjh.17363) (PMID:33620106)

Oun, H., Wilson, M. , Leach, M. and McKay, P. (2021) Central nervous system relapse of primary cutaneous CD8+ aggressive epidermotropic cytotoxic T‐cell lymphoma. British Journal of Haematology, 193(1), p. 9. (doi: 10.1111/bjh.17267) (PMID:33336793)

McKay, P., Wilson, M. R. , Chaganti, S., Smith, J., Fox, C. P. and Cwynarski, K. (2020) The prevention of central nervous system relapse in diffuse large B‐cell lymphoma: a British Society for Haematology good practice paper. British Journal of Haematology, 190(5), pp. 708-714. (doi: 10.1111/bjh.16866) (PMID:32433789)

Wilson, M. R. et al. (2020) Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery. Blood Advances, 4(15), pp. 3586-3593. (doi: 10.1182/bloodadvances.2020002421) (PMID:32761231) (PMCID:PMC7422120)

Wilson, M. R. , McKay, P. and Leach, M. (2019) Primary leptomeningeal B‐cell lymphoma. British Journal of Haematology, 187(4), p. 412. (doi: 10.1111/bjh.16163) (PMID:31423572)

Wilson, M. R. , Bagguley, T., Smith, A., Roman, E., Patmore, R., Hanlon, K., Leach, M., Burton, C. and McKay, P. (2019) Frontline management of nodular lymphocyte predominant Hodgkin lymphoma – a retrospective UK multicentre study. British Journal of Haematology, 186(6), e214-e217. (doi: 10.1111/bjh.16109) (PMID:31344253)

Hamilton, R., Andrews, I., McKay, P. and Leach, M. (2014) Loss of utility of bone marrow biopsy as a staging evaluation for Hodgkin lymphoma in the positron emission tomography–computed tomography era: a West of Scotland study. Leukemia and Lymphoma, 55(5), pp. 1049-1052. (doi: 10.3109/10428194.2013.821201)

Forbes, A., Farrell, K., McKay, P., Bolam, S. and Rule, S. (2013) High dose cytarabine with rituximab is an effective first-line therapy for mantle cell lymphoma and produces ample stem cell harvest yields after multiple chemotherapy cycles. Leukemia and Lymphoma, 54(10), pp. 2303-2305. (doi: 10.3109/10428194.2013.769536)

McKay, P., Leach, M., Jackson, R., Cook, G. and Rule, S. (2012) Guidelines for the investigation and management of mantle cell lymphoma. British Journal of Haematology, 159(4), pp. 405-426. (doi: 10.1111/bjh.12046)

Farrell, K., McKay, P. and Leach, M. (2011) Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year followup in the West of Scotland Cancer Network. Leukemia and Lymphoma, 52(10), pp. 1920-1928. (doi: 10.3109/10428194.2011.584993)

Bray, C.A., Morrison, D.S. and McKay, P. (2008) Socio-economic deprivation and survival of non-Hodgkin lymphoma in Scotland. Leukemia and Lymphoma, 49(5), pp. 917-923.